Navigation Links
Audet & Partners, LLP Files First Raptiva Lawsuit After Announced Withdrawal
Date:4/9/2009

Audet & Partners, LLP, a San Francisco, California-based trial law firm, filed the first complaint against Genentech arising out of the recently announced withdrawal of Raptiva medication. Filed in Alameda Superior Court, the complaint seeks general and punitive damages.

San Francisco, CA (PRWEB) April 9, 2009 -- Audet & Partners, LLP, a San Francisco, California-based trial law firm, filed the first complaint against Genentech arising out of the recently announced withdrawal of Raptiva medication. Filed in Alameda Superior Court (Case #rg09-446158), the complaint seeks general and punitive damages.

Raptiva is a medication used to treat severe to moderate psoriasis and works by suppressing the immune system. According to allegations in the complaint filed by Audet & Partners, LLP Raptiva allegedly causes a number of serious life-threatening infections, including encephalitis, viral meningitis and a rare brain infection known as progressive multifocal leukoencephalopathy (PML). At least three and possibly four cases of PML brain infections have been confirmed by the FDA.

Due to safety concerns, Raptiva already is suspended from the market in both Europe and Canada, and as of April 8, 2009, Genentech announced a phased withdrawal of Raptiva from the United States market.

"We have a number of clients who have contacted our firm over the past couple of months regarding Raptiva, and this is one of the first cases filed in the United States," noted William M. Audet, managing partner of Audet & Partners, LLP, "We expect that more cases will be filed by our firm as our investigation continues."

In the complaint, Plaintiff Mary Hedrick alleges that she suffered herpes viral encephalitis, a rare brain infection, as a result of being treated with Raptiva. This left her with permanent brain and nervous system damage requiring her to undergo intensive rehabilitation to relearn how to walk and speak. Plaintiff Shirley Boxell is suing on behalf of her daughter, Megan, who died of a brain infection at age 26, after taking Raptiva for one year. Plaintiff Bruce Harwell has suffered from severe leucopenia, as well as other injuries, allegedly due to Raptiva.

"All of the plaintiffs in this case have suffered serious injury while taking Raptiva, a monoclonal antibody that inhibits T-cell activity," stated Susanne Scovern, a trial attorney at Audet & Partners, LLP. "No one would choose to take a life-threatening drug for a non-life-threatening injury. The dangerous side effects of Raptiva far outweighed the good it did to treat psoriasis," she stated.

Audet & Partners, LLP, (221 Main Street, Suite 1460, San Francisco, CA 94105, 415.982.1776) a San Francisco-based law firm, represents individuals, governmental entities, small businesses and shareholders in product liability, tort, negligence, consumer, construction defect, investment fraud, securities, insider trading, antitrust, environmental, whistle blower, aviation and employment cases. The founding partner, William M. Audet, has served as court-approved lead counsel in dozens of federal and state cases throughout the United States.

# # #

Read the full story at http://www.prweb.com/releases/raptiva/lawsuit/prweb2315484.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Get Your Fruits & Veggies: CDC
2. Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer
3. Story ideas from molecular & cellular proteomics
4. Job picture for 2006 chemistry grads reasonably good, C&EN reports
5. Debut issue of Foot & Ankle Specialist
6. Congressional R&D Caucus co-chairs join scientists, engineers and graduate students
7. IU Health & Wellness: Research and insights from Indiana University
8. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
9. European Society of Human Reproduction & Embryology 24th annual meeting
10. IU Health & Wellness: New research findings from the Kinsey Institute
11. Riley Hospital for Children & Capital Institute of Pediatrics become international sister hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... ... CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware ... for diagnostic device operations. With this platform, initializing devices and importing studies are ...
(Date:5/26/2017)... Sparks, Nevada (PRWEB) , ... May 26, 2017 ... ... to produce the first ever copper, antimicrobial, mesh back 24/7 task chair specifically ... and conference applications. “We are thrilled to partner with Cupron® to provide ...
(Date:5/26/2017)... Texas (PRWEB) , ... May 26, 2017 , ... Yisrayl ... a new publication this week that is focusing on the Peace Agreements being discussed ... his Middle East sprint in a race to try to speed up peace talks ...
(Date:5/26/2017)... Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... Francisco, is proud to announce a new, informational blog post on insurance options. If ... surgery, checking insurance plans may help save time and money. Visiting an in-network provider ...
(Date:5/26/2017)... ... 26, 2017 , ... Centennial-based BluSky Restoration Contractors announced that ... Annual Clays for Kids fundraiser, to be held Friday, Sept. 22, at Kiowa ... part of BluSky’s partnership with The Adoption Exchange, BluSky will also share sponsorship ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/10/2017)... Inc. (Nasdaq: HOLX ) announced today the ... April 1, 2017 .   GAAP diluted earnings per ... prior year period as the sale of the blood ... diluted EPS of $0.50 increased 6.4%.  Revenue of $715.4 ... Excluding the effects of blood screening and the acquired ...
Breaking Medicine Technology: